Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma

Annals of Oncology

Volumn 15, Issue 1, 2004, Pages 113-117

  Comoli, P ^a   De Palma, R ^b   Siena, S ^c   Nocera, A ^d   Basso, S ^a   Del Galdo, F ^b   Schiavo, R ^c   Carminati, O ^c   Tagliamacco, A ^d   Abbate, G F ^b   Locatelli, F ^a   Maccario, R ^a   Pedrazzoli, P ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Cellular immunotherapy; Cytotoxic T lymphocytes; Epstein Barr virus; Latent membrane protein 2; Nasopharyngeal carcinoma

Indexed keywords

BLEOMYCIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; LATENT MEMBRANE PROTEIN 2; METHOTREXATE; PACLITAXEL; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CARCINOMA CELL; CASE REPORT; CELL KILLING; CELL SPECIFICITY; CYTOTOXIC T LYMPHOCYTE; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; SAFETY;

EID: 9144270460     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh027     Document Type: Article

References (17)

1. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001; 345: 1890-1900.
2. Chan ATC, Teo PML, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol 2002; 13: 1007-1015.
3. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15: 405-431.
4. Khanna R, Busson P, Burrows S et al. Molecular characterisation of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T cell epitopes by NPC cells. Cancer Res 1998; 58: 310-314.
5. Lee SP, Chan ATC, Cheung S et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol 2000; 165: 573-582.
6. Rooney CM, Smith CA, Ng CYC et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555.
7. Comoli P, Labirio M, Basso S et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99: 2592-2598.
8. Roskrow MA, Suzuki N, Gan Y et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's Disease. Blood 1998; 91: 2925-2934.
9. Chua D, Huang J, Zheng B et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharygeal carcinoma. Int J Cancer 2001; 94: 73-80.
10. De Palma R, Gorski J. Restricted and conserved T cell repertoires involved in allorecognition of class II major histocompatibility complex. Proc Natl Acad Sci USA 1995; 92: 8836-8840.
11. Yang J, Lemas VM, Flinn IW et al. Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens. Blood 2000; 95: 241-248.
12. Yee C, Thompson JA, Byrd D et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 99: 16168-16173.
13. Huls H, Popat U, Gee AP et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus-positive nasopharyngeal carcinoma. Blood 2002; 100: 121a (Abstr).
14. Comoli P, Basso S, Schiavo R et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTL) for the treatment of patients with EBV-positive relapsed nasopharingeal carcinoma. Bone Marrow Transplant 2003; 31: S207 (Abstr).
15. Lin C, Lo W, Lee T et al. Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002; 62: 6952-6958.
16. Gahn B, Siller-Lopez F, Pirooz AD et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential tratment strategy for Epstein-Barr Virus-positive Hodgkin's lymphoma. Int J Cancer 2001; 93: 706-713.
17. Gottschalk S, Edwards OL, Sili U et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003; 101: 1905-1912.